Is it safe to perform percutaneous treatment in acute pulmonary thrombosis?

Courtesy of Dr. Carlos Fava

Pulmonary embolismMassive and submassive pulmonary embolism (PE) has traditionally been treated with anticoagulation and catheter direct thrombolysis (CDT), but the safety and efficacy of this treatment has not been yet properly assessed.

 

The study analyzed 137 patients presenting acute PE massive or submassive. All patients received CTD associated to heparin by direct infusion or ultrasound assisted catheter. Infusion time was left to operators’ criteria.

 

Age was 59, half were men, 26% had a history of thromboembolism, 24% were diabetic, 82% had right ventricle compromise, and 12% had massive PE.

 

82% of cases presented bilateral PE, other 14% presented right pulmonary thrombosis, and the remaining 4% presented left pulmonary thrombosis. Thrombolysis was often ultrasound assisted (84%).

 

After thrombolysis, PASP decreased 19±15 mmHg and vena cava filters were implanted in 45% of patients.

 

5 patients died (all with massive PE). 13 patients presented major bleeding or vascular lesions; 4 presented bleeding (2 intracranial and 2 gastrointestinal), while other 6 required transfusions. There were no differences in thrombolysis technique.

 

Factors associated to complications were elderly age, massive PE and vena cava filter implantation.

 

In addition, a meta-analyzis of 16 studies with 860 patients presenting PE undergoing CDT (including this study) was carried out. Mean age was 60 (54-61), half of patients were men, and 21.6% presented massive PE.

 

After thrombolysis, PE decreased 15 mmHg. Major bleeding or vascular complications rate was 4.65%, intracranial bleeding was 0.35% and mortality was 3.4% (12.9% in massive PE and 0.74% in submassive).

 

Conclusion

Catheter direct thrombolysis is associated to low complications rate. Randomized studies should be carried out to assess its efficacy relative to anticoagulation alone.

 

Commentary

This analyzis –with a large number of patients− disregards the fact that it is possible to treat PE percutaneously, not just by injecting thrombolytics, but also by safely extracting thrombi.

 

Perhaps a stronger commitment to this condition might improve outcomes and help develop better devices or techniques.

 

Courtesy of Dr. Carlos Fava

 

Original Title: Safety of Catheter-Direct Thrombolysis for Massive and Submassive Pulmonary Embolism: Results for Massive and Submassive Pulmonary Embolism.

Reference: Tyler Blommer, et al. Catheterization and Cardiovasacular Intervention 2017:89:754-760.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

SPYRAL Program: 3-Year Outcomes in Patients Treated with Renal Denervation

Hypertension is the leading modifiable risk factor for cardiovascular disease and remains a major global health challenge, affecting more than one billion adults worldwide.  Despite...

Drug-Eluting Stents in Peripheral Arterial Disease: When Should They Be Used?

Peripheral drug-eluting stents have transformed the treatment of peripheral arterial disease by reducing restenosis rates and the need for repeat interventions. However, the emergence...

Registration Open for Module 2 of the 2026 Annual Course: Multislice CT and Cardiovascular Magnetic Resonance Imaging

The Latin American Society of Interventional Cardiology (SOLACI) and the Argentine College of Interventional Cardioangiologists (CACI) announce the opening of registration for Module 2...

EuroPCR 2026 | Is localized anticoagulation the next step for coronary stents?

The DESyne BDS Plus stent was developed as a thin-strut, bioabsorbable polymer drug-eluting stent that combines sirolimus release with two anticoagulant agents (rivaroxaban and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

SPYRAL Program: 3-Year Outcomes in Patients Treated with Renal Denervation

Hypertension is the leading modifiable risk factor for cardiovascular disease and remains a major global health challenge, affecting more than one billion adults worldwide.  Despite...

Coronary Obstruction During TAVI: A New Volumetric Index to Consider

Coronary obstruction during TAVI is an uncommon but potentially catastrophic complication, particularly in valve-in-valve procedures, in anatomies with small sinuses of Valsalva, low coronary...

EARLY TAVR: Impact of Age on Outcomes of Early TAVR in Asymptomatic Patients

Asymptomatic severe aortic stenosis represents an increasingly common clinical challenge. Although current guidelines recommend intervention once symptoms develop or left ventricular dysfunction occurs, concerns...